Online Pharmacy Service Offers Significant Cost Savings for Lung Cancer Medication

A new online pharmacy service is offering U.S. lung cancer patients a potential lifeline in managing expensive medication costs. SaveRxCanada.to is now facilitating access to Tagrisso (Osimertinib), a targeted therapy for non-small cell lung cancer (NSCLC), through licensed international suppliers at significantly reduced prices. Currently, a 30-tablet supply of Tagrisso in the United States can cost between $15,000 to $18,000 monthly. By contrast, SaveRxCanada.to's Indian suppliers offer the same AstraZeneca-branded 80 mg tablets for approximately $12,500 monthly, representing potential savings of up to $5,500 per month or $66,000 annually.

Tagrisso is a critical treatment for patients with EGFR-mutant lung cancer, specifically designed for first-line treatment and for patients whose cancer has progressed after previous EGFR-targeted therapies. The medication targets both common EGFR mutations and the resistant T790M mutation, offering improved survival outcomes and quality of life. While the medication provides significant benefits, patients should be aware of potential side effects, which include diarrhea, rash, dry skin, nail inflammation, fatigue, and decreased appetite. More rare but serious side effects can involve lung inflammation, heart rhythm problems, and eye issues.

To access the medication, patients require a valid prescription. SaveRxCanada.to's international supplier partners provide verification of product authenticity, prescription validation by licensed pharmacists, and secure shipping capabilities. This service represents a potential breakthrough for patients struggling with the high costs of cancer treatment, offering a more affordable pathway to critical medication without compromising on quality or efficacy.